The potential link between IRF8 and Tregs emerged more recently, when IRF8 mutations in relapsed DLBCL was identified as a putative marker for poor response to CD19-CAR T cells, possibly in association with an increase in Tregs in the lymphoma microenvironment (63). Here, IRF8 is linked to lymphoma.